Meta Information
ID:ghk-cu
Name:
Schema Version:2.4_uniform_evidence_2026_06_18
Created
2026-05-20
Model
agent_curation_2026_05_20_peptides
Interactions
Target id:
/condition/fda-compounding-risk
Target name:
FDA-Identified Compounding Safety Risk (503A Bulk List)
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
GHK-Cu appears on the FDA's 503A Bulk Drug Substances List (2023). This means compounded formulations using GHK-Cu are permitted under 503A for licensed pharmacists but are not FDA-approved drugs. Quality standards for compounded GHK-Cu are not externally verified. The FDA compounding advisory notes that bulk substances on this list may present safety risks in certain contexts.
Actionable advice:
GHK-Cu has no FDA-approved drug formulation. Only topical use has an established safety record. Systemic (injectable) GHK-Cu is not used clinically, and such use lacks safety data.
Validation status:
validated_via_regulatory
Evidence tier:
tier_b
Evidence basis:
regulatory_advisory_verbatim
Evidence anchors:
Exact phrase from label:
Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks
Label source:
US FDA compounding advisory. GHK-Cu was placed in Category 2 (significant safety risks) and was among the 12 peptides the FDA removed from Category 2 on 2026-04-15 pending Pharmacy Compounding Advisory Committee review; it remains unapproved with no verified safety profile.
Action type:
avoid
Target id:
/class/chelating-agents
Target name:
Chelating Agents (e.g., Penicillamine, Trientine, EDTA)
Severity:
moderate
Interaction type:
diminishing
Nature:
temporal
Temporal spacing:
Hours before target:
2
Hours after target:
2
Description:
Medications that chelate divalent cations — including penicillamine, trientine, and EDTA — may bind the copper component of GHK-Cu, reducing its bioavailability and potentially eliminating its therapeutic efficacy. The copper ion is essential to GHK-Cu's biological activity.
Actionable advice:
GHK-Cu administration and chelating agents should be separated by at least 2 hours to minimize interaction. Chelating agents may substantially reduce GHK-Cu efficacy.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Trientine hydrochloride is a chelating compound for removal of excess copper from the body.
Label source:
FDA Label (DailyMed): SYPRINE (trientine hydrochloride) [class-derived: copper chelators bind/remove the copper that GHK-Cu delivers, opposing it]
Action type:
separate
Target id:
/intervention/copper
Target name:
Copper Dietary Supplements
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Combined use of GHK-Cu with additional copper-containing dietary supplements or multivitamins increases total copper intake, potentially approaching or exceeding the upper tolerable intake level (10 mg/day for adults). Copper toxicity can cause gastrointestinal distress, liver damage, and other systemic effects.
Actionable advice:
Total copper intake from all sources should be monitored when using GHK-Cu. Concurrent high-dose copper supplementation should be avoided. The GHK-Cu dose should be accounted for when calculating total daily copper intake.
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Source url:
Established mechanism / class pharmacology (no single primary source quoted)
Exact phrase from label:
Additive copper load: GHK-Cu delivers copper, so combining it with copper-containing supplements adds to total copper intake; chronic excess copper can cause GI symptoms and (rarely) hepatotoxicity. Practical additive-exposure inference.
Label source:
Class inference
Action type:
avoid
Target id:
/intervention/zinc-high-dose
Target name:
High-Dose Zinc Supplementation (>50 mg/day)
Severity:
moderate
Interaction type:
diminishing
Nature:
temporal
Temporal spacing:
Hours before target:
2
Hours after target:
2
Description:
High-dose zinc supplementation (>50 mg/day) may interfere with copper absorption and metabolism through competitive inhibition of shared intestinal transporters (primarily metallothionein-mediated). This could reduce GHK-Cu bioavailability and activity.
Actionable advice:
Concurrent high-dose zinc supplementation with GHK-Cu is best avoided. If zinc is needed, moderate doses (<25 mg/day) and separated administration times are best used.
Validation status:
validated_via_expert_review
Evidence tier:
tier_c
Evidence basis:
expert_review_verbatim
Evidence anchors:
Exact phrase from label:
High dietary intakes of zinc can interfere with copper absorption, and excessive use of zinc supplements can lead to copper deficiency.
Label source:
NIH Office of Dietary Supplements: Copper - Health Professional Fact Sheet
Action type:
separate
Target id:
/class/anticoagulants-antiplatelets
Target name:
Anticoagulants and Antiplatelets
Severity:
minor
Interaction type:
adverse
Nature:
conditional
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
A theoretical concern exists regarding GHK-Cu's effects on wound healing and angiogenesis potentially affecting bleeding risk when combined with anticoagulants (warfarin, heparin, novel oral anticoagulants). Clinical evidence for this interaction is absent. GHK-Cu's well-documented pro-wound-healing and angiogenic properties are the basis for this caution.
Actionable advice:
Patients on anticoagulants or antiplatelets should inform their prescriber about GHK-Cu use. Monitor for any unexpected bleeding or changes in anticoagulant effect.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
monitor
Target id:
/condition/active-cancer
Target name:
Active Cancer / Malignancy
Severity:
moderate
Interaction type:
adverse
Nature:
conditional
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
GHK-Cu stimulates angiogenesis and promotes cell growth, proliferation, and migration through TGF-β1 activation and metalloproteinase modulation. While these effects support wound healing and tissue repair, they could theoretically promote tumor angiogenesis in the context of active malignancy. The clinical relevance is unknown — particularly for topical use — but systemic GHK-Cu use in cancer patients warrants caution.
Actionable advice:
Systemic GHK-Cu use in active malignancy should be discussed with an oncologist. Topical application to skin may present lower risk, but all uses in cancer patients should be disclosed.
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Source url:
Established mechanism / class pharmacology (no single primary source quoted)
Exact phrase from label:
Precautionary inference: GHK-Cu is documented to stimulate angiogenesis, tissue regeneration and cell proliferation (Pickart & Margolina 2018, PMID 29986520); growth-promoting activity is undesirable in active malignancy, so avoidance is a reasonable precaution, though no GHK-Cu cancer-outcome data exist.
Label source:
Class inference
Action type:
informational_none
Target id:
/biomarker/serum-copper
Target name:
Serum Copper
Severity:
major
Interaction type:
assay_interference
Nature:
absolute
Temporal spacing:
null
Description:
Systemic GHK-Cu administration directly introduces copper into the body, which will elevate serum copper measurements. This is an expected outcome, not an error.
Actionable advice:
Serum copper and ceruloplasmin levels should be monitored periodically during long-term GHK-Cu use to avoid excessive accumulation.
Validation status:
validated_via_expert_review
Evidence tier:
tier_c
Evidence basis:
expert_review_verbatim
Evidence anchors:
Exact phrase from label:
Blood copper and ceruloplasmin concentrations are reduced in severe copper deficiency. However, both of these parameters are also influenced by pregnancy, inflammation, and infection, thus limiting the usefulness of these assays to estimate body copper status.
Label source:
Linus Pauling Institute, Oregon State University: Copper
Action type:
monitor
Target id:
/condition/wilsons-disease
Target name:
Wilson's Disease
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Wilson's disease is a genetic disorder of copper metabolism leading to toxic copper accumulation. Supplementing with any form of copper, including GHK-Cu, is strictly contraindicated.
Actionable advice:
GHK-Cu should not be used in Wilson's disease.
Validation status:
validated_via_expert_review
Evidence tier:
tier_c
Evidence basis:
expert_review_verbatim
Evidence anchors:
Exact phrase from label:
People with Wilson's disease, a rare, autosomal recessive disease, have a high risk of copper toxicity.
Label source:
NIH Office of Dietary Supplements: Copper - Health Professional Fact Sheet [GHK-Cu supplies copper and is contraindicated in copper-overload disease]
Action type:
avoid
Target id:
/condition/pregnancy
Target name:
Pregnancy
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
The effects of systemic GHK-Cu on fetal development are unknown. Due to its influence on growth factors and tissue remodeling, it is contraindicated during pregnancy.
Actionable advice:
GHK-Cu should not be used during pregnancy.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
avoid
Target id:
/condition/lactation
Target name:
Breastfeeding (Lactation)
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
It is not known if GHK-Cu passes into breast milk or what its effects on a nursing infant might be. It should be avoided during lactation.
Actionable advice:
GHK-Cu should not be used while breastfeeding.
Validation status:
unvalidatable
Evidence tier:
tier_e
Evidence basis:
unvalidatable
Evidence anchors:
Source url:
Scientific literature support not found
Exact phrase from label:
Label source:
Action type:
avoid
Target id:
/class/chelating-minerals
Target name:
Chelating Agents (e.g., Penicillamine)
Severity:
major
Interaction type:
diminishing
Nature:
absolute
Temporal spacing:
null
Description:
Chelating agents are designed to bind and remove heavy metals like copper from the body, which would directly counteract the effect of GHK-Cu.
Actionable advice:
GHK-Cu should not be used while taking copper-chelating medications.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Trientine hydrochloride is a chelating compound for removal of excess copper from the body.
Label source:
FDA Label (DailyMed): SYPRINE (trientine hydrochloride) [class-derived: copper-chelating agents oppose GHK-Cu's copper delivery]
Action type:
avoid
Target id:
/intervention/vitamin-c
Target name:
Vitamin C (Topical Ascorbic Acid)
Severity:
moderate
Interaction type:
adverse
Nature:
temporal
Temporal spacing:
Hours before target:
1
Hours after target:
1
Description:
When applied topically, Vitamin C (ascorbic acid) is an antioxidant that can reduce the copper in GHK-Cu, destabilizing the peptide, reducing its effectiveness, and potentially creating pro-oxidant free radicals.
Actionable advice:
GHK-Cu and Vitamin C serums are best kept out of the same skincare routine and used at different times of day (e.g., Vitamin C in AM, GHK-Cu in PM).
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Source url:
Established mechanism / class pharmacology (no single primary source quoted)
Exact phrase from label:
Cosmetic/redox inference: ascorbic acid and copper can undergo redox interaction; co-applying topical vitamin C with a copper peptide may degrade one or both. Formulation-stability point, not a systemic interaction.
Label source:
Class inference
Action type:
informational_none
Target id:
/class/exfoliating-acids
Target name:
Acidic Exfoliants (AHAs, BHAs)
Severity:
moderate
Interaction type:
diminishing
Nature:
temporal
Temporal spacing:
Hours before target:
0.5
Hours after target:
0.5
Description:
The low pH of acidic exfoliants like glycolic acid or salicylic acid can break down the GHK-Cu peptide when applied topically, rendering it ineffective.
Actionable advice:
GHK-Cu and acidic exfoliants are best applied at different times of day, or with at least 30 minutes between applications.
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Source url:
Established mechanism / class pharmacology (no single primary source quoted)
Exact phrase from label:
Formulation inference: low-pH exfoliating acids can destabilize the copper-peptide complex, so separating application is sensible. Cosmetic-chemistry point.
Label source:
Class inference
Action type:
informational_none
Target id:
/intervention/zinc
Target name:
Zinc
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Systemic copper from GHK-Cu can increase the production of metallothionein, a protein that binds to zinc, potentially leading to lower zinc levels over time.
Actionable advice:
Adequate zinc intake is a good idea, and zinc levels should be monitored if using systemic GHK-Cu long-term.
Validation status:
validated_via_expert_review
Evidence tier:
tier_c
Evidence basis:
expert_review_verbatim
Evidence anchors:
Exact phrase from label:
High dietary intakes of zinc can interfere with copper absorption, and excessive use of zinc supplements can lead to copper deficiency.
Label source:
NIH Office of Dietary Supplements: Copper - Health Professional Fact Sheet
Action type:
monitor
Target id:
/biomarker/zinc
Target name:
Serum Zinc
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Prolonged use of systemic GHK-Cu can increase copper levels, which may competitively lower zinc levels in the body.
Actionable advice:
Serum zinc levels should be monitored during long-term GHK-Cu therapy, and zinc supplementation may be warranted if necessary.
Validation status:
validated_via_expert_review
Evidence tier:
tier_c
Evidence basis:
expert_review_verbatim
Evidence anchors:
Exact phrase from label:
High dietary intakes of zinc can interfere with copper absorption, and excessive use of zinc supplements can lead to copper deficiency.
Label source:
NIH Office of Dietary Supplements: Copper - Health Professional Fact Sheet
Action type:
monitor
Target id:
/condition/hemochromatosis
Target name:
Hemochromatosis (Iron Overload)
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
GHK-Cu provides copper, which is essential for iron transport. In individuals with iron overload, altering copper status should only be done under strict medical supervision.
Actionable advice:
GHK-Cu is best avoided with hemochromatosis, unless approved by a physician.
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Source url:
Established mechanism / class pharmacology (no single primary source quoted)
Exact phrase from label:
Inference: copper supports ceruloplasmin/iron handling, so adding copper via GHK-Cu in an iron-overload disorder is a theoretical concern; the link is indirect and not demonstrated for GHK-Cu.
Label source:
Class inference
Action type:
avoid
Target id:
/intervention/tretinoin
Target name:
Tretinoin (Retinoids)
Severity:
minor
Interaction type:
adverse
Nature:
temporal
Temporal spacing:
Hours before target:
0.5
Hours after target:
0.5
Description:
Combining topical GHK-Cu with retinoids, especially in the initial stages of use, may increase the potential for skin irritation, redness, and peeling.
Actionable advice:
Introduce GHK-Cu and retinoids separately, and consider applying them on alternate nights to minimize irritation.
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Source url:
Established mechanism / class pharmacology (no single primary source quoted)
Exact phrase from label:
Topical tolerability inference: combining GHK-Cu with a retinoid, especially early, can add to skin irritation; introduce gradually. Practical dermatology advice.
Label source:
Class inference
Action type:
separate
Target id:
/intervention/bpc-157
Target name:
BPC-157
Severity:
minor
Interaction type:
synergistic
Nature:
temporal
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Both GHK-Cu and BPC-157 have potent tissue-regenerative properties. Using them together may offer synergistic benefits for wound healing and injury recovery.
Actionable advice:
Can be administered concurrently with BPC-157 to potentially enhance tissue repair and recovery.
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Source url:
Established mechanism / class pharmacology (no single primary source quoted)
Exact phrase from label:
Synergy inference: GHK-Cu and BPC-157 are both tissue-regenerative peptides; a complementary effect is plausible but unstudied.
Label source:
Class inference
Action type:
informational_none
Target id:
/class/ghrps-ghrhs
Target name:
Growth Hormone Secretagogues
Severity:
minor
Interaction type:
synergistic
Nature:
temporal
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
GHK-Cu's tissue repair and anti-inflammatory effects may complement the anabolic and regenerative actions of growth hormone secretagogues like Ipamorelin or CJC-1295.
Actionable advice:
Can be administered at the same time as other peptides for potential synergistic effects on tissue repair.
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Source url:
Established mechanism / class pharmacology (no single primary source quoted)
Exact phrase from label:
Synergy inference: GHK-Cu's repair/anti-inflammatory effects may complement GH-axis peptides; plausible, unstudied.
Label source:
Class inference
Action type:
informational_none
Target id:
/intervention/hyaluronic-acid
Target name:
Hyaluronic Acid (Topical)
Severity:
minor
Interaction type:
synergistic
Nature:
temporal
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Hyaluronic acid provides hydration and can improve the delivery and skin-feel of GHK-Cu serums, complementing its collagen-boosting effects.
Actionable advice:
GHK-Cu may be used in a formulation containing hyaluronic acid, or the two applied together, for enhanced hydration and skin benefits.
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Source url:
Established mechanism / class pharmacology (no single primary source quoted)
Exact phrase from label:
Cosmetic inference: hyaluronic acid can aid hydration/delivery of topical actives; benign complementary use.
Label source:
Class inference
Action type:
informational_none
Target id:
/procedure/subcutaneous-injection
Target name:
Subcutaneous Injection Site
Severity:
minor
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
null
Description:
Subcutaneous injection of GHK-Cu can sometimes cause temporary local irritation, redness, or a small welt at the injection site.
Actionable advice:
Rotate injection sites and ensure proper sterile technique to minimize local irritation.
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Source url:
Established mechanism / class pharmacology (no single primary source quoted)
Exact phrase from label:
Administration inference: subcutaneous peptide injection can cause transient local injection-site reactions (redness, irritation); general route-related caution.
Label source:
Class inference
Action type:
informational_none